Why Ariad Pharmaceuticals (ARIA) is Soaring

NEW YORK (TheStreet) -- Ariad Pharmaceuticals (ARIA) soared during Friday's trading session, up 24.5% to $6.87 by early afternoon.

The drugmaker was popping on news its leukemia drug Iclusig could return to the market, albeit with more restrictive labeling and safety information. The medicine was suspended by the Food and Drug Administration in October on concerns it caused a higher risk of blood clots.

"Commercial distribution of Iclusig will begin by mid-January at which time we will deploy dedicated commercial and medical affairs teams in the U.S. In the meantime, patients will continue to receive Iclusig through the IND mechanism," said Ariad Executive Vice President Marty Duvall in a statement. "We expect the commercialization of Iclusig to be cash-flow positive from the onset."

More from Stocks

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Earnings Season Is Simply Out of Control Madness - How Are You Surviving?

Earnings Season Is Simply Out of Control Madness - How Are You Surviving?

Key Numbers for Investors to Watch as Amazon, Microsoft and Intel Report Results

Key Numbers for Investors to Watch as Amazon, Microsoft and Intel Report Results

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment